HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.

8th Edition of World Congress on Infectious Diseases

June 09-11, 2025 | Rome, Italy

June 09 -11, 2025 | Rome, Italy
Infection 2024

PD-associated peritonitis: A case first for Aquamicrobium

Speaker at Infectious Diseases Conferences - Ashin Mehta
Medical College of Wisconsin, United States
Title : PD-associated peritonitis: A case first for Aquamicrobium


A 56-year-old male with end-stage renal disease undergoing home peritoneal dialysis presented with abdominal pain, nausea, and altered mental status. White blood cell count was 12.3 10e3/uL, urinalysis was positive for 2+ blood, and peritoneal fluid contained a total nucleated cell count of 1840 with 98% neutrophils. The patient was empirically treated with intravenous piperacillin-tazobactam and vancomycin, and a 2% mupirocin ointment was applied around his peritoneal catheter site. Following this treatment, he showed significant symptomatic improvement. On hospital day three, the patient’s fungal culture and Methicillin-resistant Staphylococcus aureus came back negative, but his aerobic/anaerobic culture was positive for Aquamicrobium lusatiense. Aquamicrobium is an aerobic gram-negative rod which until recently had only been isolated from wastewater and contaminated soil. In 2021, two cases of Aquamicrobium infection in humans were reported. Both resulted in endophthalmitis following cataract surgery. To our knowledge, this was the third case of Aquamicrobium infection in a human and the first example of this agent causing peritonitis. Following identification of the infectious agent, the patient was transitioned to intraperitoneal vancomycin and cefepime. Two days into the new treatment course, the patient’s peritoneal fluid demonstrated a total nucleated cell count of 5 with a 40% neutrophil composition. The patient was discharged home after a seven-day inpatient stay with instructions to continue cefepime 1g via intraperitoneal injection for three weeks. On the day of discharge, his white blood cell count was 4.4 10e3/uL.


Ashin Mehta studied Human Biology at the University of Southern California, United States and graduated as BS in 2015. He then joined the research group of Dr. Thomas Anderson at Stanford University where he investigated the efficacy of focused ultrasound to inhibit nerve conduction and reduce post-operative pain. Following this, he began medical school at the Medical College of Wisconsin and will receive his MD in 2025.